Please assess the completion status of the following clinical trial:

Trial Title: A Single Arm Study Comparing ACC Supplement to CCS in Management of Hypoparathyroidism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary Hypoparathyroidism - low levels of intact PTH during hypocalcemia at diagnosis.~* Subjects receiving calcium and vitamin D supplementation at least 1 year prior to the beginning of the study.~* Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study.~* Subjects who provide written informed consent to participate in the study.~* Age: 18-80, inclusive.~Exclusion Criteria:~* Calcium (albumin corrected) serum values below 7.0 mg/dL or above 10.0 mg/dL~* Any known diseases affecting the absorption from the gastrointestinal tract:~  * Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)~ * Chronic diarrhea~* Subjects with neuropsychiatric disease.~* Subjects with impaired renal function (glomerular filtration rate, ≤40 mL/min)~* Subjects with other severe chronic disease requiring long-term therapy.~* Impaired liver function (Liver enzymes\> x3 upper limit of normal).~* Subjects with history or presence of kidney stones~* Recurrent urinary tract infections~* Subjects taking drugs which might affect calcium levels such as:~  * Fusid~ * Anticonvulsants~ * Carbonic anhydrase~ * Adrenocorticosteroids~* Subjects who are non-cooperative or unwilling to sign consent form.~* Pregnant or breast-feeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- amorphous calcium carbonate (Type: EXPERIMENTAL): Ten (10) subjects previously diagnosed and chronically treated for primary hypoparathyroidism will be enrolled. The daily CCS intake will be gradually replaced by reduced amount of elemental calcium from ACC. Five (5) subjects will consume the ACC before having a meal and the other five (5) subjects will consume the ACC after having a meal. The safety and the efficacy of the treatment will be closely monitored throughout this phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).